Human stromal cells are required for an anti-breast cancer effect of zoledronic acid

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24436-24447

  Nienhuis, Hilde H ^a   Arjaans, Marlous ^a   Timmer Bosscha, Hetty ^a   de Vries, Elisabeth G E ^a   Schröder, Carolina P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Breast cancer; CAM model; Microenvironment; TGF ; Zoledronic acid

Indexed keywords

SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; SMAD2 PROTEIN, HUMAN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHICKEN; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SENSITIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMA CELL; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BREAST TUMOR; CHEMISTRY; CHORIOALLANTOIS; COCULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHICKENS; CHORIOALLANTOIC MEMBRANE; COCULTURE TECHNIQUES; DIPHOSPHONATES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84943426510     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4421     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-322.
3. Straussman R, Morikawa T, Shee K et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-504.
4. Coleman RE, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer:A metaanalysis of individual patient data from randomised trials. Cancer Res 2013;SABCS:abstract S4-07.
5. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365:1396-1405.
6. Junankar S, Shay G, Jurczyluk J et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov 2015;5:35-42.
7. Holzapfel BM, Thibaudeau L, Hesami P, Taubenberger A, Holzapfel NP, Mayer-Wagner S, Power C, Clements J Russel P, Hutmacher DW. Humanised xenograft models of bone metastasis revisited:novel insights into speciesspecific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev 2013;32:129-145.
8. Wang J, Xia TS, Liu XA, Ding Q, Du Q, Yin H, Wang S. A novel orthotopic and metastatic mouse model of breast cancer in human mammary microenvironment. Breast Cancer Res Treat 2010;120:337-344.
9. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351-3354.
10. Lin MT, Tseng LH, Kamiyama H, Kamiyama M, Lim P, Hidalgo M, Wheelan S, Eshleman J. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. BioTechniques 2010;48:211-218.
11. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011;49:34-41.
12. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009;15:960-966.
13. Goto N, Hiyoshi H, Ito I, Tsuchiya M, Nakajima Y, Yanagisawa J. Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-β signaling pathway. Cancer Sci 2011;102:1501-1508.
14. Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL, Holen I. Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo. Clinical Cancer Res 2014;20:2922-2932.
15. Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study):final 60-month results. Ann Oncol 2012;24:398-405.
16. Davison TF. The immunologists' debt to the chicken. Br Poult Sci 2003;44:6-21.
17. Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG. Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts. BMC Biotechnol 2011;11: 124.
18. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Cancer Res 2006;12:904-916.
19. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-549.
20. 89Zr-trastuzumabF(ab')2 uptake in SKBR3 tumor xenografts. Mol Pharmaceutics 2012;9:2995-3002.
21. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, de Vries EG, de Jong IJ, Walenkamp AM. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012;14:709-718.
22. Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther 2012;11:2033-2044.
23. Turtoi A, Blomme A, Bellahcène A, Gilles C, Hennequière V, Peixoto P, Bianchi E, Noel A, de Pauw E, Lifrange E, Delvenne P, Castronovo V. Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res 2013;73:5438-5448.
24. van der Bilt AR, Terwisscha van Scheltinga AG, TimmerBosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res 2012;18:6306-6314.